Citations

Clear

3138 citation(s) found for "Smith, AM".

Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy
Roessler, Navid , Nowicka, Zuzanna , Miszczyk, Marcin , Calleris, Giorgio , Dematteis, Alessandro , Vetterlein, Malte W. , Albisinni, Simone , Poel, H J van der, Cathcart, Paul, Cacciamani, Giovanni , Persad, Raj , Joniau, Steven , Sanchez‐Salas, Rafael , Smith, Joseph A. , Karnes, R. Jeffrey , Ahmed, Mohamed E., Rajwa, Paweł , Shariat, S, Party, the Young Academic Urologists Prostate Cancer Working, Cacciamani, Giovanni E , Gill, Inderbir S , Persad, Raj A , Joniau, Steven , Sanchez-Salas, Rafael , Smith, Joseph A , Karnes, Jeffrey , Rajwa, Pawel , Tilki, Derya , Gontero, Paolo , Marra, Giancarlo , Miszczyk, Marcin , Cathcart, P. , Gill, Inderbir S. , Tilki, Derya , Shariat, Shahrokh F. , Gontero, Paolo , Marra, Giancarlo

Mayo Clinic

BJU International | June 16, 2026 | Volume: 138 | Issue: 3 | Pages: 430-437

10.1111/bju.70352 | PMID 42298374 Get It

Objectives To evaluate biochemical recurrence‐free survival (BRFS) and metastasis‐free survival (MFS) as potential intermediate clinical endpoints (ICEs) for overall survival (OS) in patients undergoing salvage radical prostatectomy (sRP). Patients and Methods Evaluable patients were selected from a retrospective dataset, resulting in a cohort of 879 patients with recurrent, non‐metastatic, hormone‐sensitive prostate cancer treated with sRP at 13 centres. ICE surrogacy was evaluated using a two‐stage approach: (i) at the individual‐patient level by fitting Clayton copula models and estimating Kendall's ( >0.7 indicating a strong association) and (ii) at the centre level, by fitting weighted linear regression of 5‐year OS on 3‐year BRFS and MFS. Results The two‐step analysis included 759 patients for BRFS (366 events) and 476 for MFS (137 events), with median follow‐up of 37 months (95% confidence interval [CI] 36–42 months) and 34 months (95% CI 31–37 months), respectively. At the individual‐patient level, MFS showed a strong association with OS (Kendall's 0.85, 95% CI 0.82–0.88), which was not observed for BRFS (Kendall's 0.63, 95% CI 0.56–0.69). At the centre level, neither 3‐year BRFS ( R 2 = 0.15; slope = 0.34, P = 0.2) nor 3‐year MFS ( R 2 = 0.21; slope = 0.26, P = 0.14) predicted 5‐year OS with sufficient explanatory power. Limitations include the fact that centre‐level analysis was based on single‐arm associations rather than on treatment‐effect surrogacy across arms, and retrospective data collection. Conclusions The BRFS should not be used as a surrogate endpoint in the sRP setting. MFS requires further validation in future prospective studies to confirm its association with OS. Patient‐reported outcomes, such as quality‐of‐life and treatment‐related toxicity, should be considered in parallel with OS.
Provider and patient perspectives on the diagnosis and treatment of Alzheimer's disease: A global perspective from the Global Alzheimer's Leadership Series (GoALS)
Andrieu, Sandrine, Bradshaw, Angela, Carmona, Ralph C., Iwatsubo, Takeshi, Hansson, Oskar, Jr, Clifford R Jack, Jicha, Gregory A, McDade, DO Eric, Mummery, Catherine J, Petersen, Ronald C, Robinson, Shelagh, Schneider, Julie A., Shellcross, Lenny, Smith, Amanda G, Snyder, Heather M. , Tapply, Beth, Teunissen, Charlotte, Flier, Wiesje M. van der, Vellas, Bruno, Williamson, Jeff D. , Wilcock, Donna, Carrillo, Maria C., Amouyel, Philippe , Andrieu, Sandrine , Bradshaw, Angela C. , Dumont, Magali , Grinberg, Lea T. , Iwatsubo, Takeshi , Hansson, Oskar , Jack, Clifford R. , Jicha, Gregory A. , Mahinrad, Simin , McDade, Eric , Mummery, Catherine J. , Petersen, Ronald C. , Schneider, Julie A. , Teunissen, Charlotte E. , Flier, Wiesje M. van der , Vellas, Bruno , Wallon, David , Carrillo, María C.

Mayo Clinic

Alzheimer's & Dementia | June 16, 2026 | Volume: 22 | Issue: 6 | Pages: No page available

10.1002/alz.71536 | PMID 42298289 Get It

Abstract Since 2016, the Alzheimer's Association and the Fondation Alzheimer have hosted Global Alzheimer's Leadership Series (GoALS) global think tanks, with world‐leading experts for innovative discussions to advance Alzheimer's disease (AD) research and care. The second GoALS think tank, held in June 2024 in Paris, focused on the relationship between biological changes and clinical manifestations of AD in the context of the evolving therapeutic landscape. Discussions spanned real‐world experiences of providers, patients, and their families, theoretical considerations, and health system challenges. The lived experience perspective was central to these discussions. The importance of shared decision‐making, clear and transparent communication, and the need for real‐world data to holistically support patients during their experiences were highlighted. This manuscript shares key insights from both the think tank meeting in Paris and a featured research session at the 2024 Alzheimer's Association International Conference that expanded the discussion themes for broader dissemination with the community.
The clinical utility of functional testing in fibroblasts to diagnose primary mitochondrial disease
Hove, Johan L.K. Van , Friederich, Marisa W. , Hove, Roxanne A. Van , Lee, Jessica C. , Knight, Kaz M. , Donovan, Tonia E, Silveira, Lori, Hirano, Michio, Abdenur, José E. , Cassiman, David, Cohen, Bruce H. , Elsea, Sarah H. , Enns, Gregory M., Gahl, William A, Gavrilova, Ralitza, Geddes, Gabriella C, Glamuzima, Emma E, Goldstein, Amy , Haas, Richard , Khan, Aneal , Kripps, Kimberly A. , Lehman, April, Lichter-Konecki, Uta, Morava, Eva, Rosenfeld, Jill A, Saneto, Russel P., Scaglia, Fernando , Shelkowitz, Emily , Smith, Wendy E, Soler-Alfonso, Claudia, Coster, Rudy N.A. Van, Vockley, Gerard, Wigby, Kristen, Wolfe, Lynne A. , Wortmann, Saskia B. , Van Hove, Johan L K , Ganetzky, Rebecca D , Cohen, Bruce H , Elsea, Sarah , Khan, Aneal , Larson, Austin A , Lehman, April N , Mayr, Johannes A , Scaglia, Fernando , Simon, Mariella , Smet, Joél E G , Tarnopolsky, Mark , Wolfe, Lynne A , Wortmann, Saskia , Yang, Jennifer H , Donovan, Tonia E., Ganetzky, Rebecca , Hirano, Michio , Butler, Merlin G. , Cassiman, David , Enns, Gregory M. , Gahl, William A. , Glamuzina, Emma E , Larson, Austin , Lichter‐Konecki, Uta , Morava, Éva , Peterson, James T. , Rosenfeld, Jill A. , Saneto, Russell P. , Smith, Wendy E. , Soler‐Alfonso, Claudia , Tarnopolsky, Mark A. , Vanlander, Arnaud Vincent , Vermeersch, Pieter , Wigby, Kristen M. , Yang, Jennifer H.

Mayo Clinic

No container title available | June 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.12.26355546 | PMID 42369463 Get It

Abstract Genome sequencing of the heterogeneous primary mitochondrial disorders (PMD) frequently reveals variants of uncertain significance that require functional tests for diagnosis, and does not identify variants in all patients. We analyzed mitochondrial enzyme assays, blue native polyacrylamide gel electrophoresis (BN-PAGE) with in-gel activity staining, complex I assembly blot, and select protein abundances in fibroblasts of a case series of 204 PMD patients divided into functional classes, in comparison to 51 controls and 53 differential diagnostic conditions. Overall, sensitivity and specificity for respiratory chain enzyme assays were 46% and 93% respectively, for BN-PAGE 40% and 98%, for complex I assembly assay 49% and 99%. The overall sensitivity of all tests was 76%, specificity 93%, with positive predictive value 96% and negative predictive value 67%. Categories with high sensitivity were isolated complex deficiencies, nuclear DNA-encoded mitochondrial protein synthesis defects, co-factor defects, and mitochondrial amino-acyl-tRNA synthetase conditions when aided by protein abundance. Mitochondrial DNA mutations and maintenance disorders showed poor sensitivities. Secondary dysfunctions were rare. A complete battery of functional tests showed strong diagnostic clinical utility in fibroblasts. One sentence summary A combination of four mitochondrial functional tests to identify or confirm suspected primary mitochondrial disease in fibroblasts had good sensitivity and excellent specificity, well beyond what was perceived using enzyme assays only.
Rotator Cuff Repair Augmentation With an Autograft Biceps Patch, the “Biceps Smash,” Results in Low Retear Rates at 6 Months and Promising Clinical Outcomes at 12 Months
Brinkman, Joseph C. , Moore, M. Lane , Smith, Casandra , Tummala, Sailesh V. , Tokish, John M. , Moore, M Lane , Tummala, Sailesh V

Mayo Clinic

Arthroscopy | June 15, 2026 | Volume: 42 | Issue: 8 | Pages: 1347-1354

10.1002/arj.70379 | PMID 42295852 Get It

Purpose To evaluate retear rates, clinical outcomes, and complications of a consecutive series of full‐thickness rotator cuff repair cases augmented with an autograft biceps patch. Methods A retrospective review was performed of patients undergoing rotator cuff repair with autograft biceps patch augmentation. Patients underwent either magnetic resonance imaging or ultrasound to evaluate rotator cuff repair integrity at a minimum of 6 months postoperatively. Patient‐reported outcomes including the American Shoulder and Elbow Surgeons Score and Single Assessment Numeric Evaluation score were also collected and evaluated for clinical significance at a minimum of 12 months postoperatively. Analysis of retear rates was performed by comparing observed retear rates to expected retear rates using the modified Rotator Cuff Healing Index score. Results The final cohort included 25 rotator cuff repair cases. Postoperative imaging was obtained by magnetic resonance imaging in 22 patients at a mean of 9 months postoperatively (range, 6.0‐15.3 months) and ultrasound in 3 patients at a mean of 30.4 months (range, 28.8‐32.2 months). The expected retear rate using the modified Rotator Cuff Healing Index score was 21.5% for the entire cohort. There was 1 retear, resulting in an actual retear rate of 4% at an average of 23.5‐month follow‐up ( P = .0196). The average Single Assessment Numeric Evaluation score was 93 (standard deviation 9), and the average American Shoulder and Elbow Surgeons Score was 96 (standard deviation 6.3) at an average of 23.5‐month follow‐up (range 14‐32). Patient acceptable symptomatic state was achieved by 96% of the cohort for the American Shoulder and Elbow Surgeons Score and 88% of the cohort for the Single Assessment Numeric Evaluation score. There were no cases of reoperation or complications. Conclusions In this consecutive series, the biceps autograft “smash” patch for rotator cuff augmentation resulted in a low rate of retears, favorable patient‐reported outcomes, and no complications. This augmentation option has the potential to be safe and effective for improving rotator cuff repair healing rates. Level of Evidence Level IV, retrospective case series.
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis
Wilson, Matthew R. , Lewis, Katharine L. , Kirkwood, Amy A., Cwynarski, Kate , Cheah, Chan Y. , El-Galaly, Tarec C., Villa, Diego , Savage, Kerry J. , Bobillo, Sabela , Smedby, Karin E. , Puckrin, Robert , Fox, Christopher P. , Bishton, Mark, Thanarajasingam, Gita , Hapgood, Greg , Soussain, Carole , Choquet, Sylvain , Mel, Sanjay De , Preston, Gavin, Hawkes, Eliza A. , Clavert, Aline, Ku, Matthew , Narkhede, Mayur , Durot, Éric , Smith, Jeffrey , Eyre, Toby A. , Ghione, Paola , E Smedby, Karin , Harrysson, Sara , Trnĕný, Marek , Puckrin, Robert , Fox, Christopher P , Thanarajasingam, Gita , Doo, Nicole Wong , Hapgood, Greg , Soussain, Carole , Choquet, Sylvain , Dickinson, Michael , Talaulikar, Dipti , Preston, Gavin , Ahearne, Matthew , Hawkes, Eliza , Schorb, Elisabeth , Clavert, Aline , Ku, Matthew , Narkhede, Mayur S , Calimeri, Teresa , Durot, Eric , Smith, Jeffrey , Renaud, Loïc , McKay, Pamela , Eyre, Toby A , Savage, Kerry J , Cheah, Chan Yoon , Lewis, Katharine L , Kirkwood, Amy, El‐Galaly, Tarec Christoffer , Ghione, Paola , Trněný, Marek , Klánová, Magdalena , Bishton, Mark , Doo, Nicole Wong , Dickinson, Michael , Talaulikar, Dipti , Guidetti, Anna

Mayo Clinic

Journal of Clinical Oncology | June 11, 2026 | Volume: 44 | Issue: 24 | Pages: 2290-2302

10.1200/jco-26-00947 | PMID 42274647 Get It

PURPOSE In large B-cell lymphoma (LBCL), use of high-dose methotrexate (HD-MTX) to prevent CNS relapse (so-called CNS prophylaxis) remains controversial. International guidelines continue to recommend HD-MTX in patients deemed ultra high risk (UHR) because of a lack of robust data specific to these subgroups. This study was designed to examine the impact of HD-MTX specifically in UHR patients. METHODS Data from two previous retrospective analyses were combined to produce a cohort of UHR patients (≥1 of the following criteria: CNS international prognostic index score 5-6; testicular, renal/adrenal, or breast involvement; ≥3 extranodal sites), treated with or without HD-MTX. The primary outcome was CNS relapse rate (isolated or concurrent with systemic relapse) measured from diagnosis with additional landmark analysis of all responding patients with no progression event at 6 months. RESULTS Analyses were performed on 1,923 patients meeting UHR criteria. No significant difference in 3-year CNS relapse rate was observed between no HD-MTX (n = 1,051) versus HD-MTX patients (n = 872), including in multivariable analyses adjusting for baseline characteristics (3-year rate, 9.3% v 8.1%; adjusted hazard ratio [HR], 1.13 [95% CI, 0.82 to 1.57]). Analyses restricted to isolated CNS relapse also confirmed no difference (5.9% v 5.7%; adjusted HR, 1.03 [95% CI, 0.69 to 1.53]). In the landmark analysis (no HD-MTX n = 782, HD-MTX n = 773), no difference in 3-year CNS relapse was observed (6.7% v 6.6%, adjusted HR, 0.95 [95% CI, 0.62 to 1.44]). CONCLUSION To our knowledge, this is the largest international comparative data set of patients with LBCL with UHR features showing no significant reduction in CNS relapse with HD-MTX in all UHR or in any individual subgroup. Despite inherent limitations of retrospective analyses, the data strongly support previous studies in suggesting HD-MTX prophylaxis has no meaningful benefit for most patients.
Pediatric epilepsy surgery: Global survey of invasive explorations
Ramantani, Georgia , Feucht, Martha , Cserpán, Dorottya , Aparicio, Javier , Arzimanoglou, Alexis , Bartoloméi, Fabrice , Bingaman, William , Braun, Kees P. J. , Burman, Richard J. , Cao, Dezhi , Caraballo, Roberto , Cloppenborg, Thomas , Cross, J. Helen , Cukiert, Cristine Mella , Curry, Daniel J. , Dimova, Petia , Eltze, Christin , Hallböök, T , Holthausen, Hans , Jayalakshmi, Sita , Jiang, Yuwu , Kannan, Lakshminarayanan , Lallas, Matt, Patil, Sandeep Bhagwan , Pérez‐Jiménez, María Ángeles, Pérez‐Poveda, Juan Carlos , Pieper, Tom , Rona, Sabine, Shetty, Jay , Smith, Mary Lou , Suwanpakdee, Piradee , Tarta‐Arsene, Oana , Tripathi, Manjari , Moosa, Ahsan N. , Weiner, Howard , Cai, Lixin , Sorbets, Sarah Ferrand , Group, ILAE Pediatric Epilepsy Surgery Taskforce and Study, Barba, Carmen , Chipaux-Raffo, Mathilde , Cloppenborg, Thomas , Cross, Helen J , Cukiert, Arthur , Curry, Daniel J , De Palma, Luca , Dimova, Petia , Eltze, Christin , Englot, Dario J , Nico Enslin, Johannes M , Fallah, Aria , Francione, Stefano , Gill, Deepak , Harvey, A Simon , Holthausen, Hans , Jayalakshmi, Sita , Jiang, Yuwu , Kannan, Lakshminarayanan , Lallas, Matt , Patil, Sandeep Bhagwan , Pérez-Poveda, Juan Carlos , San Antonio-Arce, Victoria , Shetty, Jay , Smith, Mary Lou , Suwanpakdee, Piradee , Tarta Arsene, Oana , Tassi, Laura , Tisdall, Martin M , Tripathi, Manjari , Valappil, Ahsan Moosa Naduvil , Wirrell, Elaine C , Cai, Li-Xin , Ferrand Sorbets, Sarah , Wilmshurst, Jo M , Ramantani, Georgia , Feucht, Martha , Burman, Richard J , Englot, Dario J. , Enslin, Nico , Fallah, Aria , Gill, Deepak , Pérez-Jiménez, María Ángeles, Tisdall, Martin , Wirrell, Elaine , Group, ILAE Pediatric Epilepsy Surgery Task Force and Study, Barba, Carmen

Mayo Clinic

Epilepsia | June 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70325 | PMID 42274288 Get It

Abstract Objective Invasive presurgical evaluation plays a key role in pediatric epilepsy surgery, particularly in magnetic resonance imaging (MRI)‐negative cases, by guiding resective, disconnective, or ablative procedures. This International League Against Epilepsy (ILAE) Pediatric Epilepsy Surgery Taskforce study provides an updated global overview of current invasive evaluation practices. Methods Group‐level data were collected from 61 epilepsy surgery programs (49 pediatric‐only) in 29 countries across six continents. Included were children and adolescents who underwent presurgical evaluation and epilepsy surgery in 2023. The study was designed to enable comparison with the similar ILAE survey conducted in 2004. Results A total of 2427 patients were included. Invasive evaluations were performed in 21.1% of cases, most frequently in North America (33.7%, higher than Europe: 18.0%, p = .003). Among invasive cases, 32.3% had no detectable MRI abnormalities. The main indication for invasive evaluation was seizure onset localization (88.1%), followed by motor or sensory mapping (17.2%) and language mapping (14.2%). Stereoelectroencephalography (SEEG) was the predominant technique (19.8% overall, 93.6% of invasive cases), more common in North America (30.0%, p = .021) and less common in South America (7.4%, p < .001). Subdural electrodes were used in only 3.2% of invasive cases, and combined depth and subdural approaches in 3.2%. SEEG‐guided radiofrequency thermocoagulation (RF‐TC) was performed in 40.9% of SEEG cases, most commonly in Asia (63.8%). In 16.2% of invasive evaluations, patients did not proceed to resection, disconnection, or ablation, with the highest rate in Europe (28.5%). Significance This global survey provides the first broad overview of invasive evaluation practices in pediatric epilepsy surgery across participating centers worldwide. It highlights the widespread adoption of SEEG, declining use of subdural electrodes, and increasing application of SEEG‐guided RF‐TC. The high proportion of MRI‐negative cases and the considerable proportion of patients not proceeding to resection, disconnection, or ablation underscore the complexity of contemporary surgical candidates and the need for further refinement of selection strategies.
Leptomeningeal Metastasis from Lung Cancer, a Single-center, Retrospective Cohort (P9-6.007)
Rode, Matthew, Hassan, Amna, Molina, Julian, Mansfield, A., Leventakos, Konstantinos, Dimou, Anastasios, Parikh, K, Smith, Katie, Behl, Deepti , Sener, Ugur, Rode, Matthew M. , Molina, Julian R. , Mansfield, Aaron S. , Dimou, Anastasios, Shanshal, Mohamed , Sener, Uğur

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000216806 Get It

Effectiveness of Infliximab for Refractory Non-ischemic Cerebral Enhancing Foreign-body Granulomatous Lesions Following Endovascular Therapy (P1-1.003)
Taha, Farris, Tagg, Nathan, Smith, Andrew, Flanagan, Eoin , Brown, Robert, Pittock, Sean, Perez-Giraldo, Gina, McKeon, Andrew, Aboseif, Albert , Taha, Farris , Tagg, Nathan T. , Flanagan, Eoin P. , Pittock, Sean J. , Perez-Giraldo, Gina , McKeon, Andrew

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215791 Get It

Pembrolizumab-induced Multifocal, Musicogenic, Autoimmune Epilepsy due to GAD65 Autoantibodies in a Patient Treated for Triple Negative Breast Cancer (P10-2.001)
Wright, Weston, Snehal, Isha , Cascino, Gregory, Pittock, Sean, Dubey, Divyanshu, Smith, Kelsey, Osman, Gamal, Cascino, Gregory D. , Pittock, Sean J. , Dubey, Divyanshu

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215889 Get It